Hybrid and tandem expression of Neisserial proteins
US-9011869-B2 · Apr 21, 2015 · US
Neisseria meningitidis antigens and compositions
US2016030545A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016030545-A1 |
| Application number | US-201514804756-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 21, 2015 |
| Priority date | May 1, 1998 |
| Publication date | Feb 4, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
First claim
Opening claim text (preview).
1 . (canceled) 2 . A protein comprising (i) a fragment of at least seven consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920, or (ii) an amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 3 . The protein of claim 2 comprising the fragment, wherein the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 4 . The protein of claim 3 , wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 5 . The protein of claim 3 , wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 6 . The protein of claim 2 comprising the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 7 . The protein of claim 6 , wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 8 . A composition comprising the protein of claim 2 and a pharmaceutically acceptable excipient. 9 . The composition of claim 8 , further comprising an adjuvant. 10 . The composition of claim 9 , wherein the adjuvant is an aluminum salt adjuvant. 11 . The composition of claim 10 , wherein the aluminum salt adjuvant comprises aluminum hydroxide. 12 . The composition of claim 9 , wherein the protein comprises the fragment and the fragment comprises at least ten consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 13 . The composition of claim 12 , wherein the fragment comprises at least fourteen consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 14 . The composition of claim 12 , wherein the fragment comprises at least twenty consecutive amino acids from an amino acid sequence selected from the group consisting of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 15 . The composition of claim 9 , wherein the protein comprises the amino acid sequence having at least 80% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 16 . The composition of claim 15 , wherein the amino acid sequence has at least 85% identity to one of SEQ ID NO: 2916; SEQ ID NO: 2918, and SEQ ID NO: 2920. 17 . A method of inducing an immune response in a subject comprising administering the composition of claim 9 to the subject.
Assignees
Inventors
Classifications
Bacteria · CPC title
Antibacterial agents · CPC title
Antigenic peptides or proteins · CPC title
Immunostimulants · CPC title
Immunomodulators · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016030545A1 cover?
- The invention provides proteins from Neisseria meningitidis , including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
- Who is the assignee on this patent?
- Glaxosmithkline Biolog Sa
- What technology area does this patent fall under?
- Primary CPC classification C07K14/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Feb 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).